Overpatented, Overpriced: How Excessive Pharmaceutical Patenting is Extending Monopolies and Driving up Drug Prices
Overpatented: Stats on the Top Selling Drugs
2017 Annual Report
Amicus Brief Filed in RPX Corp. v. Chanbond LLC: Patient and public interest actors should have the same rights as drugmakers to appeal IPR decisions to the courts to prevent unmerited patents.
Submission to Health and Human Services: I-MAK response to Blueprint to Lower Drug Prices
Letter to the USPTO Director
Policy Prescriptions to Solve the Drug Patent Problem
Submission to Chinese FDA: more exclusivity will harm patients
About I-MAK
Over 85% of Patients Diagnosed with Chronic Hepatitis C in the U.S. Are Currently NOT Receiving Treatment